Core Viewpoint - Zimmer Biomet has completed the acquisition of Paragon 28 for $1.2 billion, enhancing its position in the rapidly growing foot and ankle orthopedic market [1][2]. Acquisition Analysis - The acquisition was agreed upon in January 2025, with Zimmer Biomet offering $13 per share for Paragon 28, which includes a cash upfront payment and potential earn-out based on future revenue milestones [2]. - Analysts from Needham noted that Paragon 28 was a long-anticipated acquisition target and expressed surprise at the slight premium paid by Zimmer Biomet [3]. Financial Performance - Paragon 28 has shown sales growth of nearly 20%, with recent quarterly revenues between $60 million and $62 million, and an expected revenue of approximately $72 million for the fourth quarter [4]. Strategic Positioning - The acquisition allows Zimmer Biomet to enter the $5 billion global foot and ankle orthopedic market, diversifying its product offerings beyond traditional areas like hip and knee joints [5]. - Paragon 28's innovative product line, including implants and surgical solutions for foot and ankle diseases, addresses unmet patient needs and emerging opportunities [6]. Enhanced Product Portfolio - Paragon 28's tailored product offerings complement Zimmer Biomet's existing products, enabling a more comprehensive musculoskeletal solution and enhancing value propositions to healthcare providers [7]. Outpatient Surgery Center (ASC) Presence - The trend of performing more foot and ankle surgeries in ASCs aligns well with Paragon 28's solutions, providing opportunities for cross-selling other Zimmer Biomet products [10]. Global Expansion - While Paragon 28 has a strong presence in the U.S., its global influence is limited. The merger allows for accelerated global adoption of Paragon 28's products through Zimmer Biomet's established international distribution network [11]. About Paragon 28 - Paragon 28, founded in 2010 and publicly traded since October 2021, focuses on innovative surgical solutions for foot and ankle diseases, with a product range that includes fracture fixation and joint replacement [12][13]. - The company offers nearly 80 surgical systems and over 8,700 stock-keeping units (SKUs), with notable products including the Gorilla® plate system and FDA-approved 3D-printed personalized implants [15][16].

PHILADELPHIA, March 25, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of Paragon 28, Inc. (“Paragon”) (NYSE: FNA) shareholders. Click here for additional information: https://kaskelalaw.com/case/paragon-28/ On January 28, 2025, Paragon announced that it had agreed to be acquired by Zimmer Biomet Holdings, Inc. (“Zimmer”) at an upfront price of $13.00 per share in cash plus a non-tradable contingent value right (CVR) worth u ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40902 Paragon 28, Inc. (Exact name of Registrant as specified in its Charter) Delaware 27-3170186 (State or other j ...

Paragon 28, Inc. (FNA) shares ended the last trading session 8.3% higher at $12.99. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 16.2% gain over the past four weeks.Paragon 28 recorded a strong price rise on investors’ optimism surrounding an announcement by Zimmer Biomet to acquire all of the outstanding shares of Paragon 28. Zimmer Biomet agreed to buy Paragon 28 for an equity value of approximately $1.1 billi ...

Exhibit 99.2 Parac J.P. Morgan 43r Healthcare Con January 13, 20 Presenters: Albert DaCosta (CEO & Chadi Chahine (CFO and Supply Chain Operatior Forward Looking Statements Except for the historical information contained herein, the matters set forth in this presentation are forward-looking statements w "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28's potential for foot and ankle patients; its estimated net revenue for full year 202 ...

Paragon 28, Inc. (FNA) closed the last trading session at $10.31, gaining 83.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $14.40 indicates a 39.7% upside potential.The average comprises five short-term price targets ranging from a low of $12 to a high of $20, with a standard deviation of $3.36. While the lowest estimate indicates an increase of 16.4% from the current price le ...

PHILADELPHIA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against Paragon 28, Inc. (“Paragon 28” or the “Company”) (NYSE: FNA) on behalf of purchasers of Paragon 28 securities between May 5, 2023 and September 20, 2024, inclusive (the “Class Period”). Investors that suffered losses from PARAGON 28 (NYSE: FNA) investments can follow the link below for more information regarding the lawsuit: CLICK HERE to learn more about the l ...

NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Paragon 28, Inc. (NYSE: FNA) between May 5, 2023 and September 20, 2024, both dates inclusive (the “Class Period”), and those who purchased Paragon 28 call options or sold put options during the Class Period, of the November 29, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Paragon 28 securities during the ...

PHILADELPHIA, Nov. 23, 2024 (GLOBE NEWSWIRE) -- Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against Paragon 28, Inc. (“Paragon 28” or the “Company”) (NYSE: FNA) on behalf of purchasers of Paragon 28 securities between May 5, 2023 and September 20, 2024, inclusive (the “Class Period”). Investors that suffered losses from PARAGON 28 (NYSE: FNA) investments can follow the link below for more information regarding the lawsuit: CLICK HERE to learn more about the l ...

NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Paragon 28, Inc. (NYSE: FNA) between May 5, 2023 and September 20, 2024, both dates inclusive (the “Class Period”), and those who purchased Paragon 28 call options or sold put options during the Class Period, of the November 29, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Paragon 28 securities during the ...